Logo

American Heart Association

  87
  0


Final ID: We0024

Hepatic Insulin Receptors Have Divergent Effects on Apolipoprotein C3 Production and Atherogenesis in LDL Receptor-silenced Mice

Abstract Body: Elevated serum apolipoprotein C3 (APOC3) predicts cardiovascular disease risk in individuals with diabetes. APOC3 slows the clearance of atherogenic triglyceride-rich lipoproteins (TRLs) and their remnants (RLPs). We assessed the hypothesis that hepatic insulin receptor (IR) deficiency causes increased APOC3 levels, altered lipid profiles, and enhanced atherosclerosis. Liver-specific IR deficiency was induced in adult IR-floxed mice fed a high-fat high-sucrose diet by administering a liver-targeted adeno-associated virus expressing Cre recombinase (TBG-AAV8-Cre). Controls received empty TBG-AAV8 (n=5/group). Two weeks later, a liver-targeted LDL receptor (LDLR) antisense oligonucleotide was injected biweekly for 8 weeks. Mice deficient in hepatic IRs exhibited modestly elevated blood glucose (229 ± 12 [mean ± SEM] vs 167 ± 7 mg/dL in controls; p=0.001) and plasma cholesterol (639 ± 61 vs 409 ± 40 mg/dL; p=0.0004). Plasma insulin levels were markedly elevated (7.2 ± 1.3 vs 0.6 ± 0.3 ng/mL; p=0.008). Plasma triglycerides and free fatty acids did not differ between the groups. However, IR-deficient mice showed reduced hepatic Apoc3 mRNA levels and a dramatic reduction in plasma APOC3 (413 ± 82 vs 1774 ± 183 μg/mL; p=3.68x10-8). Apolipoprotein kinetics were analyzed by targeted mass spectrometry after 13C15N-lysine injection. Hepatic IR-deficient mice exhibited a strikingly reduced APOC3 production rate (30.5 ± 10.1 vs 146.8 ± 59.6 μg/mL/h; p=0.008) with no difference in fractional clearance rate (FCR). Plasma APOB100 levels were also reduced (155.0 ± 29.6 vs 296.5 ± 38.0 mg/dL, p=0.03) with a lower production rate (0.027 ± 0.006 vs 0.128 ± 0.045 mg/mL/h; p=0.03) and no difference in FCR. APOE production rates and FCRs of APOA1, APOA2, APOA4, APOC1, APOC2, and APOE were also similar between the groups. Despite the exceedingly low APOC3 and APOB100 levels, hepatic IR-deficient mice had increased levels of cholesterol-enriched TRLs/RLPs and a striking increase in both total aortic and aortic sinus atherosclerotic lesions (p=1.73x10-10). In summary, hepatic IR deficiency in adult LDLR-deficient mice leads to reduced plasma APOC3 and APOB100 levels by suppressing their production rates but paradoxically increases cholesterol-enriched TRLs/RLPs and atherosclerosis. Our study suggests that hepatic IRs regulate lipid metabolism and atherogenesis partly independently of APOC3, and underscores the complexity of IR-mediated regulation of cardiovascular disease risk.
  • Khang, Ah Reum  ( UNIVERSITY OF WASHINGTON , Seattle , Washington , United States )
  • Kanter, Jenny  ( UNIVERSITY OF WASHINGTON , Seattle , Washington , United States )
  • Bornfeldt, Karin  ( UNIVERSITY OF WASHINGTON , Seattle , Washington , United States )
  • Shimizu-albergine, Masami  ( UNIVERSITY OF WASHINGTON , Seattle , Washington , United States )
  • Shao, Baohai  ( UNIVERSITY OF WASHINGTON , Seattle , Washington , United States )
  • Tang, Jingjing  ( UNIVERSITY OF WASHINGTON , Seattle , Washington , United States )
  • Kramer, Farah  ( UNIVERSITY OF WASHINGTON , Seattle , Washington , United States )
  • Den Hartigh, Laura  ( UNIVERSITY OF WASHINGTON , Seattle , Washington , United States )
  • Tran, Alan  ( UNIVERSITY OF WASHINGTON , Seattle , Washington , United States )
  • Luo, Jason  ( UNIVERSITY OF WASHINGTON , Seattle , Washington , United States )
  • Mullick, Adam  ( Ionis Pharmaceuticals, Inc. , Carlsbad , California , United States )
  • Author Disclosures:
    Ah Reum Khang: DO NOT have relevant financial relationships | Jenny Kanter: DO NOT have relevant financial relationships | Karin Bornfeldt: DO have relevant financial relationships ; Advisor:Esperion Therapeutics:Active (exists now) | Masami Shimizu-Albergine: No Answer | Baohai Shao: No Answer | Jingjing Tang: DO NOT have relevant financial relationships | Farah Kramer: No Answer | Laura Den Hartigh: DO NOT have relevant financial relationships | Alan Tran: No Answer | Jason Luo: No Answer | Adam Mullick: DO have relevant financial relationships ; Employee:Ionis Pharmaceuticals:Active (exists now)
Meeting Info:
Session Info:

08. Poster Session 2 & Reception Sponsored by the ATVB Journal

Wednesday, 04/23/2025 , 05:00PM - 07:00PM

Poster

More abstracts on this topic:
Assessing the Efficacy and Safety of Olezarsen in Lowering Triglyceride Levels: A Systematic Review and Meta-Analysis

Shahzad Zoha, Batool Asma, Ijaz Osama, Rao Asad Gul, Rasool Warda, Wani Shariq Ahmad, Rauf Faateh, Ilmaguook Badr, Khan Arslan Ahmed, Bhatti Ali Hanif

B-type Natriuretic Peptide Reverses Vascular Endothelial Insulin Resistance and Ameliorates Oxidative Stress in Human Atherosclerosis

Foran Daniel, Krasopoulos George, Srivastava Vivek, Sayeed Rana, Antonopoulos Alexios, Channon Keith, Akoumianakis Ioannis, Antoniades Charalambos, Badi Ileana, Polkinghorne Murray, Katsouda Antonia, Riering Marianne, Dalessio Andrea, Sastry Priya, Kourliouros Antonios, Walcot Nicholas

More abstracts from these authors:
Type 1 diabetes mellitus and atherosclerosis

Bornfeldt Karin, Kanter Jenny

Lipid-loaded Myeloid Cells Accumulate in Atherosclerotic Lesions and Kidneys in a Mouse Model of Cardiovascular-Kidney-Metabolic Syndrome: Lack of Protective Effects of Hematopoietic CD36-Deficiency

Cervantes Jocelyn, Kanter Jenny, Kramer Farah, Tran Alan, Luo Jason, Mullick Adam, Limonote Christine, Bjornstad Petter, Bansal Nisha, Bornfeldt Karin

You have to be authorized to contact abstract author. Please, Login
Not Available